Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements. Through the biochemical modulation of 5-fluorouracil (5-FU) with folinic acid (FA), the use of infusional rather than bolus regimens and the combination of 5-FU/FA with other active agents (notably irinotecan), first-line response rates (RRs) of 40% can be achieved, with patients surviving up to 17 months. Significant benefits on survival are also seen with second-line chemotherapy. The question of how best to sequence combination chemotherapy was addressed in a recent trial in which patients were randomized to receive either an irinotecan-based combination with 5-FU/FA (FOLFIRI) followed by an oxaliplatin-based combination (FOLFOX), or the two regimens in the reverse order. In both arms, RRs were greater than 50% and median survival exceeded 20 months. The primary end point was time to progression after two lines of treatment, and this was not significantly different. However, the sequence FOLFIRI followed by FOLFOX appears preferable because of the better tolerability of FOLFIRI in first-line use. Use of the sequence FOLFIRI/FOLFOX is also supported by the greater chance of a second-line response with FOLFOX. Concern has been expressed about the safety of irinotecan combined with bolus 5-FU/FA. Infusional regimens have a better risk/benefit ratio than bolus regimens. However, the adverse event profile with both approaches is manageable, and irinotecan plus 5-FU/FA can be considered one standard of care in metastatic CRC.

[1]  R. Goldberg,et al.  A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer , 2005, British Journal of Cancer.

[2]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[3]  S. Tafuto,et al.  Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Grothey Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) , 2002 .

[6]  E. Van Cutsem,et al.  Toxicity of irinotecan in patients with colorectal cancer. , 2001, The New England journal of medicine.

[7]  E. Van Cutsem,et al.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Peters,et al.  Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  M. Seymour,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[10]  D. Sargent,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[11]  R. James,et al.  Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. , 2001, European journal of cancer.

[12]  A. Grothey,et al.  Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC) , 2001 .

[13]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[14]  M. Rothenberg Efficacy of oxaliplatin in the treatment of colorectal cancer. , 2000, Oncology.

[15]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Jonker,et al.  Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials , 2000, British Journal of Cancer.

[17]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[18]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[19]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[20]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Bleiberg Role of chemotherapy for advanced colorectal cancer: new opportunities. , 1996, Seminars in oncology.

[22]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[23]  Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.